Tests MORF-057 for moderately to severely active Crohn's disease
Tests MORF-057 against placebo in adults with active Crohn's disease.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Key facts
- Where
- Almaty, Astana, Karaganda, and Shymkent, KazakhstanSee the 6 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderately to severely active Crohn's disease who did not do well on, or could not tolerate, earlier treatment.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Moderately to severely active Crohn's disease, with signs or symptoms for at least 90 days before screening. CDAI score of 220 to 450. SES-CD score of 6 or more (4 or more if the disease is only in the ileum).
- Earlier treatment
- Must have had an inadequate response, loss of response, or intolerance to at least one of: corticosteroids, immunosuppressants (such as azathioprine, 6-mercaptopurine, methotrexate), or advanced therapies (such as biologic agents, JAK inhibitors). Must not have had vedolizumab or other integrin inhibitors, or MORF-057.
Main reasons for not taking part
- Other types of colitis, or ulcerative colitis
- Crohn's disease only in the mouth, stomach, duodenum, jejunum or perianal area
- Large bowel resection (more than 100 cm (3 ft 3 in) or more than 3 resections) or short bowel syndrome
- Tube feeding, formula diet or total parenteral nutrition
- Major neurological disorder, such as stroke or multiple sclerosis
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT06226883, who can take part
Where in Kazakhstan
- Scientific Research Institute of Cardiology and Internal Disease of the Ministry of Health of the Republic of KazakhstanAlmaty, KazakhstanTaking people
- National Research Medical CenterAstana, KazakhstanTaking people
- Sana ClinicAstana, KazakhstanNo longer taking part
- Karaganda Medical UniversityKaraganda, KazakhstanTaking people
- "Gastromed" Medical CenterShymkent, KazakhstanTaking people
- Diagnostic Center of ShymkentShymkent, KazakhstanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Trial code
- NCT06226883EU 2023-508158-24-00
- Record updated
- 4 November 2026
- Original description
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).Read full original descriptionShow less
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Inclusion: Has signs/symptoms of CD for at least 90 days prior to screening; Has a CDAI score of 220 to 450, with an average daily stool subscore ≥4 points and/or an average daily abdominal pain subscore of ≥2 points; Has an SES-CD score of ≥6 (or an SES-CD score of ≥4 if CD is isolated to the ileum); Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: Corticosteroids, Immunosuppressants (eg, azathioprine, 6-mercaptopurine, methotrexate) and/or advanced therapies for CD (eg, biologic agents, Janus kinase [JAK] inhibitors, applicable investigational products).
Exclusion: Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or UC, or has clinical findings suggestive of UC; Is currently receiving total parenteral nutrition, tube feeding, or a formula diet; Has a concurrent, clinically significant, serious, unstable comorbidity; Previous treatment with vedolizumab or other licensed or investigational integrin inhibitors; Is currently participating in any other interventional study or has received any investigational therapy within 30 days; Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057; Has had extensive bowel resection (>100 cm), and/or more than 3 resections, and/or has a known diagnosis of short bowel syndrome; Has a history of any major neurological disorders, including: stroke, multiple sclerosis, brain tumor, demyelinating, or neurodegenerative disease; Has CD that is isolated to the oral cavity, stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement; Has positive findings on a subjective neurological screening questionnaire; Unable to attend study visits or comply with study procedures.